Trastuzumab-dttb - Biologic Drug Details

Summary for trastuzumab-dttb

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for trastuzumab-dttb

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	HER2/neu Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for trastuzumab-dttb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for trastuzumab-dttb Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for trastuzumab-dttb Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Trastuzumab-dttb

Last updated: February 20, 2026

What is trastuzumab-dttb?

Trastuzumab-dttb is a biosimilar of trastuzumab (Herceptin), approved for HER2-positive breast and gastric cancers. It employs the same monoclonal antibody mechanism, targeting the HER2 receptor.

Regulatory approvals and regional launches

• Approved by the FDA in August 2021 under the biosimilar pathway.
• Approved by the EMA in September 2021.
• Launched in the United States and European markets in late 2021 and early 2022.
• Additional approvals in Japan (2022) and South Korea (2022).

Market size and forecast

Global HER2-positive cancer therapeutics market

Year	Market Size (USD billions)	CAGR (%)
2022	8.2	8.3
2027	13.4	10.7

Forecast assumes increased quadrivalent biosimilar adoption, driven by cost savings and expanded access.

Biosimilar penetration

• Biosimilars account for approximately 25% of HER2 therapy sales in 2022.
• Expected to reach 50% penetration by 2027.

Pricing overview

Product	Average Annual Cost (USD)	Price Reduction vs Original (%)
Trastuzumab (Herceptin)	70,000	0
Trastuzumab-dttb	45,000	36

The substantial price differential influences market share growth.

Sales and revenue trajectory

Trastuzumab-dttb sales (USD millions)

Year	Estimated Sales	Growth Rate (%)
2022	300	—
2023	600	100
2024	1,000	66.7
2025	1,500	50
2026	2,200	46.7

Factors influencing sales growth

• Competitive biosimilar landscape.
• Healthcare policies favoring biosimilar uptake.
• Expanding indications and off-label uses.
• Cost savings driving formulary acceptance.

Patent landscape and biosimilar competition

• Original trastuzumab patents expired in key markets (US in 2019, EU in 2018).
• Multiple biosimilars, including trastuzumab-dttb, launched post-expiration.
• Entry of biosimilars led to a 20-30% reduction in trastuzumab's global sales since 2020.

Reimbursement and payer policies

• Countries adopting biosimilars link reimbursement rates to biosimilar market share.
• Price negotiations favor biosimilars, often reducing prices by 30-50% compared to originator.
• US CMS includes biosimilar uptake metrics in hospital payment adjustments.

Commercial challenges

• Physician and patient confidence in biosimilars.
• Prescriber incentives and educational programs.
• Competition from other biosimilars and originating biologics.

Strategic considerations

• Biotech firms focus on expanding indications, including adjuvant therapy for early-stage cancers.
• Partnership deals aim to improve market access.
• Investment in manufacturing scale to meet rising demand.

Key market risks

• Regulatory delays or restrictions.
• Market saturation and price erosion.
• Clinical uncertainties around biosimilarity acceptance.

Conclusion

Trastuzumab-dttb’s market will continue expanding, driven by cost advantages, regulatory acceptances, and increased biosimilar adoption. Its revenue trajectory depends on competitive dynamics, healthcare policies, and innovation efforts to broaden indications.

---

Key Takeaways

• Trastuzumab-dttb entered markets post-patent expiry, amid aggressive biosimilar competition.
• Projected to reach USD 2.2 billion by 2026, boosted by cost savings and policy shifts.
• Biosimilar penetration is expected to double within five years, affecting originator sales.
• Pricing strategies and reimbursement frameworks heavily influence market share.
• Continued innovation and indication expansion will be vital for sustaining growth.

---

FAQs

1. How does trastuzumab-dttb compare price-wise with the originator trastuzumab?
It costs approximately 36% less annually, around USD 45,000 versus USD 70,000 for Herceptin.

2. What is the expected timeline for biosimilar market share growth?
Biosimilars are projected to reach roughly 50% of HER2 therapy sales by 2027.

3. Which regions showed early adoption of trastuzumab-dttb?
The US, EU, Japan, and South Korea led in approvals and launches during 2021-2022.

4. What are major barriers to biosimilar adoption?
Physician and patient perceptions, reimbursement constraints, and market saturation.

5. How does patent expiration influence the biosimilar market?
Patent expiry in 2018–2019 facilitated multiple biosimilar entries, intensifying competition and reducing originator sales.

---

References

1. [1] Healthcare Innovation. (2022). Biosimilar market analysis: HER2-positive treatments.
2. [2] FDA. (2021). Biosimilar product approvals.
3. [3] European Medicines Agency. (2021). Biosimilar medicines: Regulatory pathways.
4. [4] GlobalData. (2022). HER2 cancer treatment market forecast.
5. [5] IQVIA. (2022). Biosimilar uptake and market dynamics.